G01N 33/57565
Involving carcinoembryonic antigen [cea]
Official title: {involving carcinoembryonic antigen [CEA]}
G01N33/57565 (Involving carcinoembryonic antigen [cea]) appears on 66 US grants and 81 published applications in this corpus.
Search patents in G01N- Granted patents
- 66
- Published applications
- 81
- Assignees
- 73
- Inventors
- 269
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 4 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 5 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 2 |
| 2005 | 1 | 4 |
| 2006 | 0 | 4 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 2 | 3 |
| 2010 | 0 | 4 |
| 2011 | 1 | 2 |
| 2012 | 1 | 4 |
| 2013 | 1 | 3 |
| 2014 | 1 | 4 |
| 2015 | 2 | 1 |
| 2016 | 2 | 4 |
| 2017 | 3 | 3 |
| 2018 | 0 | 2 |
| 2019 | 3 | 4 |
| 2020 | 2 | 5 |
| 2021 | 3 | 2 |
| 2022 | 2 | 8 |
| 2023 | 4 | 2 |
| 2024 | 1 | 5 |
| 2025 | 1 | 7 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-CEACAM5 antibodies and uses thereof10 Mar 2026US 12,570,761 B2Sanofi
- Anti-CEACAM6 antibodies and methods of use18 Feb 2025US 12,227,570 B2Agency for Science, Technology and Research
- CEACAM1 based point-of-care cancer diagnostic29 Oct 2024US 12,130,287 B2
- Anti-CEACAM6 antibodies and methods of use21 Nov 2023US 11,820,821 B2Agency for Science, Technology and Research
- Antibodies against carcinoembryonic antigens3 Oct 2023US 11,774,452 B2American Diagnostics & Therapy, LLC
- Methods for analyzing lung cancer associated proteomic markers27 Aug 2026US 2026/0251657 A1PrognomIQ, Inc.
- Methods for distinguishing lung cancer from non-cancer27 Aug 2026US 2026/0251663 A1PrognomIQ, Inc.
- Integrated decentralized identity-based system for wearable body-fluid detection, biochemical assaying, evidence-chain verification, triage routing, and lifelong health management with multi-modal confirmation20 Aug 2026US 2026/0243768 A1
- Multi-analyte diagnostic and prognostic assays for colorectal cancer and uses thereof14 May 2026US 2026/0132469 A1New Day Diagnostics, LLC
- Hybrid metal nanoparticles for ultrafast detection of pancreatic ductal adenocarcinoma25 Dec 2025US 2025/0389722 A1Georgia Tech Research Corporation
Most cited
By later US patents
- Methods for detecting nucleic acids indicative of cancer159US 6,964,846 B1Exact Sciences Corporation · 2005
- Devices for performing ion-capture binding assays142US 5,670,381 AAbbott Laboratories · 1997
- Method of producing monoclonal anti-idiotype antibody132US 4,699,880 AImmunomedics, Inc. · 1987
- Method and device for measuring a target substance in a liquid sample103US 5,219,762 AMochida Pharmaceutical Co., Ltd. · 1993
- CEA-family antigens, Anti-CEA antibodies and CEA immunoassay97US 4,818,709 A1989